Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
View Patent ↗The invention features methods and selenium-containing compositions for treating a neoplastic disease in a subject. In particular, the invention features methods for enhancing sensitivity of a tumor to cancer therapy by treating the tumor with an inorganic selenium-containing (iSe) compound and with a cancer therapy, particularly a cancer therapy that also affects the cellular redox status of a tumor cell (e.g., radiation).
1. A method of treating prostate cancer in a subject, the method comprising:
administering to a subject having prostate cancer a pharmaceutically acceptable salt of an inorganic selenium-containing compound (iSe compound) in an amount effective to alter a reduction-oxidation state of a prostate cancer cell toward oxidation; and
administering radiation therapy to the subject within 6 hours after administering the iSe compound;
wherein administering the iSe compound and radiation therapy provides for a synergistic effect in treating the prostate cancer in the subject.
2. The method of claim 1 , wherein the iSe compound is inorganic selenite.
3. The method of claim 1 , wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.
4. The method of claim 1 , wherein said administering of the iSe compound is intravenous, tumor targeted, intratumoral, peritumoral, or oral.
5. The method of claim 1 , wherein the iSe compound is administered within 2 hours prior to administering the radiation therapy.
6. The method of claim 1 , wherein the iSe compound is selenite.
7. The method of claim 6 , wherein the pharmaceutically acceptable salt of the iSe compound is a sodium salt.
8. The method of claim 1 , wherein the prostate cancer is androgen-responsive.
9. The method of claim 1 , wherein the prostate cancer is androgen-resistant.
10. The method of claim 1 , wherein the iSe compound is inorganic selenate.
11. The method of claim 1 , wherein the administering comprises intravenously administering about 0.25 mg/Kg of the pharmaceutically acceptable salt of iSe compound.
12. A method of enhancing sensitivity of prostate cancer in a subject to radiation therapy, the method comprising:
administering to a subject having prostate cancer a pharmaceutically acceptable salt of an inorganic selenium-containing compound (iSe compound) in an amount effective to sensitize the prostate cancer to radiation therapy; and
administering the radiation therapy to the subject within 6 hours after administering the iSe compound;
wherein administration of the iSe compound is effective to enhance sensitivity of the tumor to the radiation therapy by providing a synergistic effect in enhancing sensitivity of the prostate cancer to the radiation therapy.
13. The method of claim 12 , wherein inorganic selenium-containing compound is inorganic selenite.
14. The method of claim 12 , wherein the prostate cancer is androgen-responsive.
15. The method of claim 12 , wherein the prostate cancer is androgen- resistant.
16. The method of claim 12 , wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.
17. The method of claim 12 , wherein the administering of the iSe compound is intravenous, tumor targeted, intratumoral, peritumoral, or oral.
18. The method of claim 12 , wherein the administering comprises intravenously administering about 0.25 mg/Kg or more of the pharmaceutically acceptable salt of iSe compound.
19. The method of claim 12 , wherein the pharmaceutically acceptable salt of an iSe compound is sodium selenite.
20. A method of treating prostate cancer, the method comprising:
administering to a subject having prostate cancer a pharmaceutically acceptable salt of an inorganic selenite, wherein the salt of the inorganic selenite is sodium selenite; and
administering radiation therapy to the subject within 6 hours after administering the pharmaceutically acceptable salt of an inorganic selenite;
wherein administering the pharmaceutically acceptable salt of an inorganic selenite and the radiation therapy provides for a synergistic effect in prostate cancer cell growth inhibition to treat the prostate cancer.
21. The method of claim 20 , wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.
22. The method of claim 20 , wherein the administering of the iSe compound is intravenous, tumor targeted, intratumoral, peritumoral, or oral.
23. The method of claim 20 , wherein the administering comprises intravenously administering about 0.25 mg/Kg or more of the pharmaceutically acceptable salt of an inorganic selenite.
24. The method of claim 20 , wherein the prostate cancer is androgen-responsive.
25. The method of claim 20 , wherein the prostate cancer is androgen- resistant.